| scholarly article | Q13442814 |
| P50 | author | Lars Wallentin | Q6230815 |
| Agneta Siegbahn | Q43407505 | ||
| Tomas Jernberg | Q61894825 | ||
| John Brandt | Q87611018 | ||
| Joseph M Jakubowski | Q96255992 | ||
| Hideo Naganuma | Q125203128 | ||
| P2093 | author name string | Christopher D Payne | |
| Kenneth J Winters | |||
| Christelle Darstein | |||
| P2860 | cites work | The difference between clopidogrel responsiveness and posttreatment platelet reactivity | Q28210845 |
| Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q28213485 | ||
| The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties | Q41906079 | ||
| Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. | Q44545487 | ||
| Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study | Q44604925 | ||
| Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction | Q45056639 | ||
| Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention | Q46421411 | ||
| Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction | Q28168881 | ||
| Controversies in antiplatelet therapy for patients with cardiovascular disease | Q28174695 | ||
| Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement | Q28174756 | ||
| Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial | Q28181168 | ||
| Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials | Q28181957 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Durability of platelet inhibition by clopidogrel | Q28195768 | ||
| Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity | Q28196405 | ||
| Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation | Q28196513 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspirin | Q18216 |
| patient | Q181600 | ||
| clopidogrel | Q410237 | ||
| coronary artery disease | Q844935 | ||
| platelet aggregation | Q14913634 | ||
| P304 | page(s) | 1166-73 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease | |
| P478 | volume | 27 |
| Q61806944 | A Review of Antiplatelet Activity of Traditional Medicinal Herbs on Integrative Medicine Studies |
| Q35870016 | A Study of Platelet Inhibition, Using a 'Point of Care' Platelet Function Test, following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction [PINPOINT-PPCI]. |
| Q39989728 | A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats |
| Q36649213 | A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease |
| Q41868121 | A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans |
| Q50276492 | A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study |
| Q85832851 | A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial |
| Q38475429 | A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel |
| Q37813151 | Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable |
| Q38101275 | Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents |
| Q36302146 | Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review |
| Q58481433 | Antiplatelet drugs |
| Q35752619 | Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q37684794 | Antiplatelet therapies for the treatment of cardiovascular disease |
| Q37751998 | Antiplatelet therapy for atherothrombotic disease: how can we improve the outcomes? |
| Q37798110 | Antiplatelet therapy in acute coronary syndromes |
| Q46494893 | Antiplatelet therapy in acute coronary syndromes |
| Q37965609 | Antiplatelet therapy in acute coronary syndromes. |
| Q36941850 | Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives |
| Q37714189 | Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. |
| Q37313410 | Antithrombotic therapies in primary angioplasty: rationale, results and future directions |
| Q37997963 | Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus |
| Q37709191 | Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus |
| Q37953778 | Arterial thrombosis--insidious, unpredictable and deadly |
| Q34771381 | Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance |
| Q38132923 | Assessing post-treatment platelet reactivity: a focus on patient selection and setting. |
| Q39159683 | Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome |
| Q39204251 | Cangrelor for treatment during percutaneous coronary intervention |
| Q33165093 | Cardiac purinergic signalling in health and disease |
| Q38520990 | Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner |
| Q89751378 | Clinical Implications of "Tailored" Antiplatelet Therapy in Patients With Chronic Total Occlusion |
| Q21710717 | Clinical profile of prasugrel, a novel thienopyridine |
| Q64917565 | Clinical safety profile of ticagrelor compared to clopidogrel in 1208 patients: Real world evidence. |
| Q51906913 | Clopidogrel poor responders: an objective definition based on Bayesian classification. |
| Q38274517 | Clopidogrel resistance: the way forward |
| Q46253334 | Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. |
| Q38008466 | Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications |
| Q95424391 | Comparative pharmacokinetics/pharmacodynamics of clopidogrel besylate and clopidogrel bisulfate in healthy Korean subjects |
| Q38065124 | Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. |
| Q46091293 | Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. |
| Q54028729 | Comparison of platelet aggregation response in switching regimen from prasugrel to clopidogrel between CYP2C19 extensive versus non-extensive metabolizers. |
| Q87488294 | Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction |
| Q51748167 | Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. |
| Q37629641 | Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. |
| Q36688145 | Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial |
| Q34280678 | Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes |
| Q37782412 | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention |
| Q37781893 | Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery |
| Q45918932 | Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes. |
| Q51048521 | Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome. |
| Q38578616 | Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents |
| Q79954598 | Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently |
| Q28546587 | Discovering anti-platelet drug combinations with an integrated model of activator-inhibitor relationships, activator-activator synergies and inhibitor-inhibitor synergies |
| Q43015908 | Early stent thrombosis with progressive brainstem infarction in a clopidogrel non-responder |
| Q37429557 | Effect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study |
| Q42632671 | Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial |
| Q46234082 | Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects |
| Q42646492 | Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel |
| Q46184936 | Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials |
| Q42978644 | Elinogrel: pharmacological principles, preclinical and early phase clinical testing |
| Q34716730 | Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. |
| Q42822406 | Emerging Oral Antiplatelet Therapies for Acute Coronary Syndromes |
| Q38121144 | Emerging antithrombotic drugs for acute coronary syndrome. |
| Q37959155 | Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes |
| Q41020546 | Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects |
| Q37988850 | Evolving role of platelet function testing in coronary artery interventions |
| Q37841568 | Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists |
| Q37259929 | Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease |
| Q51905748 | Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. |
| Q50039596 | Haemostaseological complication management in caval and iliac venous stenting |
| Q48246774 | Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. |
| Q57153950 | Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study |
| Q38391222 | High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. |
| Q26824850 | High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance |
| Q33595926 | Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions |
| Q38444425 | Impact of tailored anti-P2Y12 therapies in acute coronary syndromes |
| Q38025446 | Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel |
| Q37498604 | Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel |
| Q49386697 | In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris |
| Q38071262 | Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease. |
| Q37973397 | InforMatrix: ADP antagonists in acute coronary syndromes |
| Q45918033 | Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. |
| Q33561577 | Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent |
| Q50944358 | Lessons learned in the drug-eluting stent era. |
| Q37486610 | Long-term effect of chronic oral anticoagulation: focus on coronary artery disease |
| Q30239853 | Management standards for stable coronary artery disease in India |
| Q37641606 | Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans |
| Q38063289 | Modern antiplatelet agents in coronary artery disease |
| Q37608580 | Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence |
| Q46789035 | Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting |
| Q37304566 | New antiplatelet agents for cardiovascular disease |
| Q36865090 | New antiplatelet therapies for acute coronary syndromes |
| Q37768334 | New antithrombotic agents--insights from clinical trials |
| Q38180991 | New antithrombotics for secondary prevention of acute coronary syndrome. |
| Q82447685 | New era in antiplatelet therapy based on results from recent clinical trials |
| Q37825548 | Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome |
| Q37925007 | Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome |
| Q28221328 | Optimal management of platelet function after coronary stenting |
| Q28218094 | Optimizing platelet P2Y12 inhibition for patients undergoing PCI |
| Q57460606 | Oral antiplatelet agents in cardiovascular disease |
| Q33554381 | Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement |
| Q35797491 | Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options |
| Q35141555 | Overcoming aspirin resistance with loading clopidogrel earlier in elective percutaneous coronary intervention. |
| Q37562606 | P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. |
| Q38542096 | P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use |
| Q37339517 | P2Y12 inhibitors in cardiovascular disease: focus on prasugrel |
| Q37969927 | P2Y12 platelet inhibition in clinical practice |
| Q38420789 | P2Y12 receptor inhibitors for secondary prevention of ischemic stroke |
| Q38051192 | P2Y12 receptor: platelet thrombus formation and medical interventions. |
| Q38014344 | PAR-1 antagonists: current state of evidence |
| Q42164176 | Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial |
| Q37590925 | Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials |
| Q37927151 | Pharmacokinetic basis of the antiplatelet action of prasugrel |
| Q43288118 | Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor |
| Q43187673 | Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects |
| Q36787291 | Pharmacological antithrombotic adjuncts to percutaneous coronary intervention |
| Q38101963 | Pharmacotherapy for the reduction of stent thrombosis |
| Q26862694 | Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments |
| Q37310828 | Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future |
| Q37579228 | Platelet P2Y12 receptor inhibition by thienopyridines: status and future |
| Q38068348 | Platelet function monitoring and clopidogrel |
| Q37590046 | Platelet function testing and implications for clinical practice |
| Q53736763 | Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome. |
| Q38132252 | Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know |
| Q46235035 | Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease |
| Q28210429 | Prasugrel |
| Q37818331 | Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development |
| Q37479088 | Prasugrel for the treatment of patients with acute coronary syndrome |
| Q38972064 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients |
| Q37451509 | Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. |
| Q60189656 | Prasugrel in critically ill patients |
| Q54580380 | Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. |
| Q90273293 | Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis |
| Q37905028 | Prasugrel resistance: fact or fiction |
| Q46840686 | Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans |
| Q45988813 | Prasugrel. |
| Q37641320 | Prasugrel: a critical comparison with clopidogrel. |
| Q37171568 | Prasugrel: a novel antiplatelet agent |
| Q37579188 | Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q37486601 | Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention |
| Q46761762 | Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation |
| Q30827217 | Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). |
| Q38340126 | Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention |
| Q64903262 | Rationale, Design, and Baseline Characteristics of the Prospective Japan Acute Myocardial Infarction Registry (JAMIR). |
| Q37679209 | Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care |
| Q44264585 | Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report |
| Q38038255 | Review of ticagrelor in the management of acute coronary syndromes |
| Q37809630 | Review: Antiplatelet drugs: what comes next? |
| Q42024923 | Role of sodium tungstate as a potential antiplatelet agent |
| Q36090735 | Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction |
| Q92226447 | Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention |
| Q35176063 | Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease |
| Q28217585 | Stent thrombosis: consider also low response to antiplatelets |
| Q42000079 | Successful prasugrel rescue therapy in clopidogrel resistant patients who had recurrent stent thrombosis of drug-eluting-stent: the role of prasugrel in clopidogrel nonresponders |
| Q38009746 | Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist |
| Q46527034 | Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects |
| Q39380453 | TP-58, a novel thienopyridine derivative, protects mice from concanavalinA-induced hepatitis by suppressing inflammation |
| Q37925009 | TRITON and beyond: new insights into the profile of prasugrel |
| Q45972272 | Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting. |
| Q39010701 | The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. |
| Q46735703 | The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses |
| Q46894672 | The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities |
| Q51816112 | The discovery and development of prasugrel. |
| Q37923969 | The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders |
| Q89586527 | The p48 Flow Modulation Device with Hydrophilic Polymer Coating (HPC) for the Treatment of Acutely Ruptured Aneurysms: Early Clinical Experience Using Single Antiplatelet Therapy |
| Q90710642 | The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy |
| Q37380507 | The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes |
| Q46591786 | The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function |
| Q41469702 | Therapeutic uses of epicatechin in diabetes and cancer |
| Q37838124 | Thienopyridines in Acute Coronary Syndrome |
| Q89731964 | Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes |
| Q53084647 | Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. |
| Q34043989 | Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial |
| Q38557198 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? |
| Q37552005 | Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist |
| Q48163588 | Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome. |
| Q37486605 | Update on oral antiplatelet therapy: principles, problems and promises |
| Q38161394 | Updates in antiplatelet agents used in cardiovascular diseases |
| Q53267036 | Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. |
| Q37704842 | What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel |
| Q85893287 | [Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration] |
| Q83592968 | [Periinterventional antiplatelet therapy: from bench to bedside] |
Search more.